Cargando…
Lung Fibrosis after COVID-19: Treatment Prospects
At the end of 2019, a highly contagious infection began its ominous conquest of the world. It was soon discovered that the disease was caused by a novel coronavirus designated as SARS-CoV-2, and the disease was thus abbreviated to COVID-19 (COVID). The global medical community has directed its effor...
Autores principales: | Bazdyrev, Evgeny, Rusina, Polina, Panova, Maria, Novikov, Fedor, Grishagin, Ivan, Nebolsin, Vladimir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398080/ https://www.ncbi.nlm.nih.gov/pubmed/34451904 http://dx.doi.org/10.3390/ph14080807 |
Ejemplares similares
-
The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia
por: Bazdyrev, Evgeny, et al.
Publicado: (2022) -
Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial
por: Bazdyrev, Evgeny, et al.
Publicado: (2022) -
Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases
por: Rusina, Polina, et al.
Publicado: (2023) -
Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
por: Skurikhin, Evgenii, et al.
Publicado: (2020) -
Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis
por: Medina-De la Garza, Carlos Eduardo, et al.
Publicado: (2022)